Biotech Analysts, along with expert Dr. Juan Pablo Frias, discuss recent developments and data from the GLP-1 field, including pemvi, on an Analyst/Industry conference call to be held on February 10 at 11 am. Webcast Link
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ALT:
- Guggenheim views Altimmune risk/reward heading into MOMENTUM as attractive
- Know Who to Follow! Here are the Top Female Analysts of 2022
- Cantor Fitzgerald biotech analyst to hold analyst/industry conference call
- Altimmune management to meet virtually with Piper Sandler
- Altimmune price target raised to $25 from $14 at Evercore ISI
